ClinicalTrials.gg
CompletedNCT02182830Updated Jul 31, 2018Results posted

24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension

A Phase 3 interventional study of Empagliflozin low dose and placebo in Diabetes Mellitus, Type 2 and Hypertension, sponsored by Boehringer Ingelheim. Completed at 92 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-07-31.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
166
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim — 2 open to participants now, 3 under way, 2 of them phase 3. Diabetes Mellitus, Type 2 · Boehringer Ingelheim.

Enrollment
63rd of 96
166 · median 302
Started
2014
with 6 others
Phase 3
50 of 130
2 open now
Registered
84th of 130
by date

Among the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim, this one is the 63rd largest by enrollment of the 96 interventional ones that give a count, is one of 7 that started in 2014, is one of 50 in phase 3, and was the 84th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

2 of the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim, or all of them as a file.
02

Study summary

This trial is designed to investigate the efficacy and safety of empagliflozin compared with placebo in hypertensive black/African Americans with type 2 Diabetes Mellitus. Since hyperglycaemia and hypertension are key risk factors for both micro- and macrovascular complications, assessment of both glucose and BP lowering effects of empagliflozin in hypertensive African American patients with type 2 Diabetes Mellitus could provide clinically highly relevant, new information for the use of empagliflozin.

Essential hypertension is four times more common in African Americans than in Caucasians.

One of the risk factors for hypertension is sodium sensitivity and approximately one third of the essential hypertensive population is responsive to sodium intake. There is a higher association of hypertension with sodium sensitivity in African American patients with type 2 Diabetes Mellitus.

The treatment duration of this trial (24 weeks) will enable assessment of the clinically relevant endpoint of a decrease in HbA1c, a well accepted measurement of chronic glycaemic control and the key secondary endpoints of decreases in systolic BP (SBP) and diastolic BP (DBP) at 12 and 24 weeks.

03

Conditions studied

  • Diabetes Mellitus, Type 2
  • Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Type 2 Diabetes Mellitus (T2DM) prior to .
  • Male and female black/African American patients on diet and exercise regimen who are EITHER drug-naïve (defined as absence of any oral antidiabetic therapy, glucagon like peptide-1 (GLP-1) analog or insulin for 12 weeks, 16 weeks for pioglitazone prior to randomisation) OR pre-treated with stable dose of

    • Metformin only, or
    • Sulfonylurea only, or
    • Dipeptidyl peptidase-4 (DPP-4) inhibitor only, or
    • metformin plus sulfonylurea, or
    • metformin plus DPP-4 inhibitor. Treatment has to be unchanged for a minimum of 12 weeks prior to randomization. Dose for metformin: maximum tolerated dose The maximum daily dose of Sulfonylurea (SU) or DPP-4 inhibitor should not exceed that stated in the local label.
  • of >= 7.0% (53 mmol/mol) and ≤ 11.0% (97 mmol/mol) at Visit 1 (screening).
  • Mean seated Systolic Blood Pressure (SBP) 140-180 mmHg at Visit 1 (screening).
  • Successful completion of baseline Ambulatory Blood Pressure Monitor (ABPM) testing with a mean SBP 135-175 mmHg prior to randomisation.
  • Treatment with stable doses of at least one but not more than 4 antihypertensive medication >= 4 weeks prior to randomisation.
  • Age >= 18 years at Visit 1 (screening)
  • Signed and dated written informed consent by date of Visit 1 in accordance with Good Clinical Practice (GCP) and local legislation

Exclusion criteria

Exclusion criteria:

  • Uncontrolled hyperglycemia with a glucose level >270 mg/dl (>15.0 mmol/L) after an overnight fast during placebo run-in (includes Visit 2.1) and confirmed by a second measurement (not on the same day).
  • Exposure to any other antidiabetic medication within 12 weeks prior to randomisation other than metformin, sulfonylurea, Dipeptidyl peptidase-4 (DPP-4) inhibitor, metformin plus sulfonylurea or metformin plus DPP-4 inhibitor.
  • Current hypertension treatment with oral Minoxidil (topical minoxidil for hair growth is allowed).
  • Mean seated Systolic Blood Pressure (SBP) ≥181 mmHg during placebo run-in visit and confirmed by a second measurement (not on the same day) preferably within one day.
  • Upper arm circumference that exceeds the upper circumference level of the cuff size of either Ambulatory Blood Pressure Monitor (ABPM) and/or (BP) measurement device used in the study.
  • Night shift workers who routinely sleep during the daytime and/or whose work hours include midnight.
  • Diagnosis of diabetes/Type I diabetes mellitus, monogenic (neonatal or maturity onset diabetes of the young (MODY)) diabetes or Type I diabetes in adults/latent autoimmune diabetes of adults (LADA) per investigator or patient medical history at the time of Visit 1 (screening).
  • Known or suspected secondary hypertension (e.g. renal artery stenosis,phaeochromocytoma, Cushing's disease).
  • History or evidence of hypertensive retinopathy (Keith-Wagener grade III or IV) and/or hypertensive encephalopathy.
  • valvular heart disease or severe aortic stenosis in the opinion of the investigator.
  • Acute coronary syndrome (non- ST wave elevated myocardial infarction (STEMI), STEMI and unstable angina pectoris), stroke or within 3 months prior to .
  • Indication of liver disease, defined by serum levels of either (ALT) (Serum Glutamic Pyruvate Transaminase(SGPT)), Aspartate Aminotransferase (AST) (Serum Glutamic Oxaloacetic Transaminase (SGOT)), or alkaline phosphatase above 3 x (ULN) as determined during screening and/or run-in phase.
  • Impaired renal function, defined as Estimated (eGFR)\< 45 ml/min/1.73m2 (moderate renal impairment, chronic kidney disease epidemiology collaboration Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula) as determined during screening and/or run-in phase.
  • Bariatric surgery within the past two years and other gastrointestinal surgeries that induce chronic malabsorption.
  • Medical history of cancer (except for basal cell carcinoma) and/or treatment for cancer within the last 5 years.
  • Blood dyscrasias or any disorders causing hemolysis or unstable Red Blood Cells (e.g. malaria, babesiosis, haemolytic anaemia, thalassemia, sickle cell anaemia (sickle cell trait is allowed)).
  • Medical history and signs and symptoms of diabetic autonomic neuropathy.
  • Treatment with anti-obesity drugs 3 months prior to randomisation (i.e. surgery, aggressive diet regimen, etc.) leading to unstable body weight.
  • Current treatment with systemic at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent or any other uncontrolled endocrine disorder except Type 2 Diabetes Mellitus (T2DM) in the opinion of the investigator.
  • Pre-menopausal women (last menstruation \<=1 year prior to informed consent) who:

    • are nursing or pregnant or
    • are of and are not practicing an acceptable method of , or do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in the trial. Acceptable methods of birth control include tubal ligation, transdermal patch, intra uterine devices/systems (IUDs/IUSs), oral, implantable or injectable contraceptives, complete sexual abstinence (if acceptable by local authorities), double barrier method and vasectomised partner.
  • Alcohol, drug or confectionary liquorice abuse within the 3 months prior to informed consent that would interfere with trial participation or any ongoing condition leading to a decreased compliance to study procedures or study drug intake in the investigator's opinion.
  • Intake of an drug in another trial within 30 days prior to intake of study medication in this trial; or participating in another trial (involving an investigational drug and/or follow-up) after discontinuing medication in that trial.
  • Any other clinical condition that would jeopardize patient's safety while participating in this clinical trial in the opinion of the investigator.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
166 participants (actual)

Study arms

  • Experimental
    Empagliflozin

    starting dose 10mg; forced titration after 4 weeks 25mg dose

    Drug: Empagliflozin low dose · Drug: Empagliflozin high dose

  • Placebo comparator
    Placebo

    starting dose 10mg; forced titration after 4 weeks 25mg dose

    Drug: placebo

Interventions

  • DrugEmpagliflozin low dose

    starting dose 10mg; forced titration after 4 weeks 25mg dose

  • Drugplacebo

    starting dose 10mg; forced titration after 4 weeks 25mg dose

  • DrugEmpagliflozin high dose

    starting dose 10mg; forced titration after 4 weeks 25mg dose

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Glycated Haemoglobin (HbA1c) (%) at 24 Weeks

    Change from baseline in HbA1c (%) at 24 weeks is presented. The term "baseline" refers to the last observation prior to randomisation of the patient. Means presented are the adjusted means. Restricted maximum likelihood (REML)-based mixed model repeated measures (MMRM) model is used in the statistical analysis.

    Time frame: baseline and 24 weeks

Secondary outcomes

  1. Change From Baseline in Mean 24-hour Ambulatory Systolic Blood Pressure (SBP) at Week 12

    Change from baseline in mean 24-hour ambulatory Systolic blood pressure SBP at Week 12 is presented. The term "baseline" refers to the last observation prior to randomisation of the patient. Means presented are the adjusted means. This is a key secondary endpoint

    Time frame: baseline and 12 weeks

  2. Changes From Baseline in Trough Mean Ambulatory SBP at Week 12

    Changes from baseline in trough mean ambulatory SBP at Week 12 is presented. The term "baseline" refers to the last observation prior to randomisation of the patient. Means presented are the adjusted means. This is a key secondary endpoint

    Time frame: baseline and 12 weeks

  3. Change From Baseline in Body Weight at Week 24

    Changes from baseline in body weight at Week 24 is presented. The term "baseline" refers to the last observation prior to randomisation of the patient. Means presented are the adjusted means. This is a key secondary endpoint

    Time frame: baseline and 24 weeks

  4. Change From Baseline in Trough Seated SBP at Week 12

    Change from baseline in trough seated SBP (mmHg) at Week 12 is presented. The term "baseline" refers to the last observation prior to randomisation of the patient. Means presented are the adjusted means. This is a key secondary endpoint

    Time frame: baseline and 12 weeks

  5. Change From Baseline in Mean 24-hour Ambulatory SBP (mmHg) at Week 24

    Change from baseline in mean 24-hour ambulatory SBP (mmHg) at Week 24 is secondary endpoint. The term "baseline" refers to the last observation prior to randomisation of the patient. Means presented are the adjusted means.

    Time frame: baseline and 24 weeks

  6. Change From Baseline in Mean 24-hour Ambulatory Diastolic Blood Pressure (DBP) at Week 12

    Change from baseline in mean 24-hour ambulatory DBP (mmHg) at Week 12. The term "baseline" refers to the last observation prior to randomisation of the patient. Means presented are the adjusted means.

    Time frame: baseline and 12 weeks

  7. Change From Baseline in Mean 24-hour Ambulatory DBP (mmHg) at Week 24

    Change from baseline in mean 24-hour ambulatory DBP (mmHg) at Week 24 is secondary endpoint. The term "baseline" refers to the last observation prior to randomisation of the patient. Means presented are the adjusted means.

    Time frame: baseline and 24 weeks

  8. Change From Baseline in Trough Seated SBP (mmHg) at Week 24

    Change from baseline in trough seated SBP (mmHg) at Week 24 is secondary endpoint. The term "baseline" refers to the last observation prior to randomisation of the patient. Means presented are the adjusted means.

    Time frame: baseline and 24 weeks

  9. Change From Baseline in Trough Seated DBP (mmHg) at Week 12

    Change from baseline in trough seated DBP (mmHg) at Week 12 is secondary endpoint. The term "baseline" refers to the last observation prior to randomisation of the patient. Means presented are the adjusted means.

    Time frame: baseline and 12 weeks

  10. Change From Baseline in Trough Seated DBP (mmHg) at Week 24

    Change from baseline in trough seated DBP (mmHg) at Week 24 is secondary endpoint. The term "baseline" refers to the last observation prior to randomisation of the patient. Means presented are the adjusted means.

    Time frame: baseline and 24 weeks

07

Results

Posted Jul 31, 2018

Participant flow

In this Phase 3b, multi-centre trial, a total of 719 patients were screened by 92 centres across the United States. The first centre was initiated on 25 Jul 2014. Of the 719 screened patients, 297 patients entered the placebo run-in phase of the trial and 166 were subsequently randomised to double-blind treatment

Participant flow — Overall Study
MilestonePlaceboEmpagliflozin 10 Mg-25mg
Started8383
Randomised set (rs)7982
Treated set (ts)7780
Completed6868
Not completed1515
Withdrew: Not treated11
Withdrew: Trial stopped, reason missing33
Withdrew: Consent withdrawn88
Withdrew: Lost to follow-up33

Outcome measures

PrimaryChange From Baseline in Glycated Haemoglobin (HbA1c) (%) at 24 Weeks

Change from baseline in HbA1c (%) at 24 weeks is presented. The term "baseline" refers to the last observation prior to randomisation of the patient. Means presented are the adjusted means. Restricted maximum likelihood (REML)-based mixed model repeated measures (MMRM) model is used in the statistical analysis.

Time frame:
baseline and 24 weeks
Reported as:
Mean · percentage of glycated haemoglobin
Change From Baseline in Glycated Haemoglobin (HbA1c) (%) at 24 Weeks
percentage of glycated haemoglobinPlaceboEmpagliflozin 10 Mg-25mg
Change From Baseline in Glycated Haemoglobin (HbA1c) (%) at 24 Weeks0.07 ± 0.14-0.71 ± 0.14
Statistical analysis
  • Placebo vs Empagliflozin 10 Mg-25mg · Mixed Models Analysis · p = 0.0002 · Adjusted mean difference: -0.78 · 95% CI -1.18 to -0.38Empagliflozin minus Placebo
SecondaryChange From Baseline in Mean 24-hour Ambulatory Systolic Blood Pressure (SBP) at Week 12

Change from baseline in mean 24-hour ambulatory Systolic blood pressure SBP at Week 12 is presented. The term "baseline" refers to the last observation prior to randomisation of the patient. Means presented are the adjusted means. This is a key secondary endpoint

Time frame:
baseline and 12 weeks
Reported as:
Mean · millimeter of mercury (mmHg)
Change From Baseline in Mean 24-hour Ambulatory Systolic Blood Pressure (SBP) at Week 12
millimeter of mercury (mmHg)PlaceboEmpagliflozin 10 Mg-25mg
Change From Baseline in Mean 24-hour Ambulatory Systolic Blood Pressure (SBP) at Week 12-0.90 ± 1.47-6.10 ± 1.41
Statistical analysis
  • Placebo vs Empagliflozin 10 Mg-25mg · ANCOVA · p = 0.0117 · Adjusted mean difference: -5.21 · 95% CI -9.24 to -1.18Empagliflozin minus Placebo
SecondaryChanges From Baseline in Trough Mean Ambulatory SBP at Week 12

Changes from baseline in trough mean ambulatory SBP at Week 12 is presented. The term "baseline" refers to the last observation prior to randomisation of the patient. Means presented are the adjusted means. This is a key secondary endpoint

Time frame:
baseline and 12 weeks
Reported as:
Mean · millimeter of mercury (mmHg)
Changes From Baseline in Trough Mean Ambulatory SBP at Week 12
millimeter of mercury (mmHg)PlaceboEmpagliflozin 10 Mg-25mg
Changes From Baseline in Trough Mean Ambulatory SBP at Week 12-1.00 ± 1.89-6.99 ± 1.80
Statistical analysis
  • Placebo vs Empagliflozin 10 Mg-25mg · ANCOVA · p = 0.0237 · Adjusted mean difference: -5.99 · 95% CI -11.16 to -0.81Empagliflozin minus Placebo
SecondaryChange From Baseline in Body Weight at Week 24

Changes from baseline in body weight at Week 24 is presented. The term "baseline" refers to the last observation prior to randomisation of the patient. Means presented are the adjusted means. This is a key secondary endpoint

Time frame:
baseline and 24 weeks
Reported as:
Mean · kilogram (kg)
Change From Baseline in Body Weight at Week 24
kilogram (kg)PlaceboEmpagliflozin 10 Mg-25mg
Change From Baseline in Body Weight at Week 24-0.98 ± 0.42-2.21 ± 0.41
Statistical analysis
  • Placebo vs Empagliflozin 10 Mg-25mg · Mixed Models Analysis · p = 0.0382 · Adjusted mean difference: -1.23 · 95% CI -2.39 to -0.07Empagliflozin minus Placebo
SecondaryChange From Baseline in Trough Seated SBP at Week 12

Change from baseline in trough seated SBP (mmHg) at Week 12 is presented. The term "baseline" refers to the last observation prior to randomisation of the patient. Means presented are the adjusted means. This is a key secondary endpoint

Time frame:
baseline and 12 weeks
Reported as:
Mean · mmHg
Change From Baseline in Trough Seated SBP at Week 12
mmHgPlaceboEmpagliflozin 10 Mg-25mg
Change From Baseline in Trough Seated SBP at Week 12-3.94 ± 1.82-7.97 ± 1.83
Statistical analysis
  • Placebo vs Empagliflozin 10 Mg-25mg · Mixed Models Analysis · p = 0.1215 · Adjusted mean difference: -4.04 · 95% CI -9.16 to 1.09Empagliflozin minus Placebo
SecondaryChange From Baseline in Mean 24-hour Ambulatory SBP (mmHg) at Week 24

Change from baseline in mean 24-hour ambulatory SBP (mmHg) at Week 24 is secondary endpoint. The term "baseline" refers to the last observation prior to randomisation of the patient. Means presented are the adjusted means.

Time frame:
baseline and 24 weeks
Reported as:
Mean · mmHg
Change From Baseline in Mean 24-hour Ambulatory SBP (mmHg) at Week 24
mmHgPlaceboEmpagliflozin 10 Mg-25mg
Change From Baseline in Mean 24-hour Ambulatory SBP (mmHg) at Week 24-1.94 ± 1.94-10.33 ± 1.85
Statistical analysis
  • Placebo vs Empagliflozin 10 Mg-25mg · Mixed Models Analysis · p = 0.0025 · Adjusted mean difference: -8.39 · 95% CI -13.74 to -3.04Empagliflozin minus Placebo
SecondaryChange From Baseline in Mean 24-hour Ambulatory Diastolic Blood Pressure (DBP) at Week 12

Change from baseline in mean 24-hour ambulatory DBP (mmHg) at Week 12. The term "baseline" refers to the last observation prior to randomisation of the patient. Means presented are the adjusted means.

Time frame:
baseline and 12 weeks
Reported as:
Mean · mmHg
Change From Baseline in Mean 24-hour Ambulatory Diastolic Blood Pressure (DBP) at Week 12
mmHgPlaceboEmpagliflozin 10 Mg-25mg
Change From Baseline in Mean 24-hour Ambulatory Diastolic Blood Pressure (DBP) at Week 12-0.37 ± 0.90-3.80 ± 0.86
Statistical analysis
  • Placebo vs Empagliflozin 10 Mg-25mg · ANCOVA · p = 0.0069 · Adjusted mean difference: -3.43 · 95% CI -5.90 to -0.96Empagliflozin minus Placebo
SecondaryChange From Baseline in Mean 24-hour Ambulatory DBP (mmHg) at Week 24

Change from baseline in mean 24-hour ambulatory DBP (mmHg) at Week 24 is secondary endpoint. The term "baseline" refers to the last observation prior to randomisation of the patient. Means presented are the adjusted means.

Time frame:
baseline and 24 weeks
Reported as:
Mean · mmHg
Change From Baseline in Mean 24-hour Ambulatory DBP (mmHg) at Week 24
mmHgPlaceboEmpagliflozin 10 Mg-25mg
Change From Baseline in Mean 24-hour Ambulatory DBP (mmHg) at Week 24-1.48 ± 1.24-6.38 ± 1.20
Statistical analysis
  • Placebo vs Empagliflozin 10 Mg-25mg · Mixed Models Analysis · p = 0.0058 · Adjusted mean difference: -4.91 · 95% CI -8.35 to -1.46Empagliflozin minus Placebo
SecondaryChange From Baseline in Trough Seated SBP (mmHg) at Week 24

Change from baseline in trough seated SBP (mmHg) at Week 24 is secondary endpoint. The term "baseline" refers to the last observation prior to randomisation of the patient. Means presented are the adjusted means.

Time frame:
baseline and 24 weeks
Reported as:
Mean · mmHg
Change From Baseline in Trough Seated SBP (mmHg) at Week 24
mmHgPlaceboEmpagliflozin 10 Mg-25mg
Change From Baseline in Trough Seated SBP (mmHg) at Week 24-2.83 ± 1.82-10.26 ± 1.70
Statistical analysis
  • Placebo vs Empagliflozin 10 Mg-25mg · Mixed Models Analysis · p = 0.0036 · Adjusted mean difference: -7.43 · 95% CI -12.37 to -2.48Empagliflozin minus Placebo
SecondaryChange From Baseline in Trough Seated DBP (mmHg) at Week 12

Change from baseline in trough seated DBP (mmHg) at Week 12 is secondary endpoint. The term "baseline" refers to the last observation prior to randomisation of the patient. Means presented are the adjusted means.

Time frame:
baseline and 12 weeks
Reported as:
Mean · mmHg
Change From Baseline in Trough Seated DBP (mmHg) at Week 12
mmHgPlaceboEmpagliflozin 10 Mg-25mg
Change From Baseline in Trough Seated DBP (mmHg) at Week 12-2.30 ± 1.09-4.14 ± 1.10
Statistical analysis
  • Placebo vs Empagliflozin 10 Mg-25mg · Mixed Models Analysis · p = 0.2402 · Adjusted mean difference: -1.84 · 95% CI -4.93 to 1.25Empagliflozin minus Placebo
SecondaryChange From Baseline in Trough Seated DBP (mmHg) at Week 24

Change from baseline in trough seated DBP (mmHg) at Week 24 is secondary endpoint. The term "baseline" refers to the last observation prior to randomisation of the patient. Means presented are the adjusted means.

Time frame:
baseline and 24 weeks
Reported as:
Mean · mmHg
Change From Baseline in Trough Seated DBP (mmHg) at Week 24
mmHgPlaceboEmpagliflozin 10 Mg-25mg
Change From Baseline in Trough Seated DBP (mmHg) at Week 24-1.30 ± 1.09-5.55 ± 1.02
Statistical analysis
  • Placebo vs Empagliflozin 10 Mg-25mg · Mixed Models Analysis · p = 0.0053 · Adjusted mean difference: -4.25 · 95% CI -7.21 to -1.29Empagliflozin minus Placebo

Adverse events

Collected over All adverse events occurring after the first dose of trial medication up to a period of 7 days after the last dose of trial medication (i.e. end of REP); up to 25 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/80 (0%)4/80 (5%)8/77 (10.4%)
Empagliflozin 10 Mg-25mg0/82 (0%)3/82 (3.7%)12/80 (15%)
Most frequent serious events
Most frequent serious events
EventPlaceboEmpagliflozin 10 Mg-25mg
Chest painGeneral disorders1/801/82
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/800/82
Cerebrovascular accidentNervous system disorders1/800/82
AsthmaRespiratory, thoracic and mediastinal disorders1/800/82
Cardiac failure congestiveCardiac disorders0/801/82
Drug-induced liver injuryHepatobiliary disorders0/801/82
OverdoseInjury, poisoning and procedural complications0/801/82
Most frequent other events
Most frequent other events
EventPlaceboEmpagliflozin 10 Mg-25mg
Lipase increasedInvestigations3/776/80
CoughRespiratory, thoracic and mediastinal disorders1/775/80
Upper respiratory tract infectionInfections and infestations4/772/80

Baseline characteristics

Full analysis set (FAS): All patients randomised, treated with at least one dose of trial drug, and with a baseline and at least one on-treatment glycated haemoglobin (HbA1c)value. The FAS was the basis for the primary efficacy analysis.

Age, Continuous
Age, Continuous(years)PlaceboEmpagliflozin 10 Mg-25mgTotal
Mean57.2 ± 9.356.5 ± 9.356.8 ± 9.3
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboEmpagliflozin 10 Mg-25mgTotal
Female363571
Male364379
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboEmpagliflozin 10 Mg-25mgTotal
Hispanic or Latino000
Not Hispanic or Latino7278150
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboEmpagliflozin 10 Mg-25mgTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American7278150
White000
More than one race000
Unknown or Not Reported000
Baseline hemoglobin A1c (HbA1c) [%]
Baseline hemoglobin A1c (HbA1c) [%](percentage of HbA1c)PlaceboEmpagliflozin 10 Mg-25mgTotal
Mean8.51 ± 1.128.66 ± 0.928.59 ± 1.02
Baseline estimated glomerular filtration rate (eGFR)
Baseline estimated glomerular filtration rate (eGFR)(mL/min/1.73m²)PlaceboEmpagliflozin 10 Mg-25mgTotal
Mean91.49 ± 20.7991.15 ± 18.9591.31 ± 19.79
08

Study locations

92 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35205, United States
  • Clinical Research Advantage, Inc./Rita B. Chuang, MD, LLC
    Birmingham, Alabama 35211, United States
  • Longwood Research
    Huntsville, Alabama 35801, United States
  • Internal Medicine Center, LLC
    Mobile, Alabama 36608, United States
  • Mobile Medical and Diagnostic Center
    Mobile, Alabama 36617, United States
  • University of South Alabama
    Mobile, Alabama 36617, United States
  • Cardiology and Medicine Clinic
    Little Rock, Arkansas 72204, United States
  • Larry Watkins, M .D.
    Little Rock, Arkansas 72205, United States
  • eStudySite
    Chula Vista, California 91911, United States
  • Torrance Clinical Research Institute Inc.
    Lomita, California 90717, United States
  • Long Beach Center for Clinical Research
    Long Beach, California 90807, United States
  • MD Clinical Trials
    Los Angeles, California 90025, United States
  • Office of Dr. Alexander Ford, M.D.
    Los Angeles, California 90035, United States
  • Diabetes Associates Medical Group
    Orange, California 92868, United States
  • Integrated Research Group, Inc.
    Riverside, California 92506, United States
  • Clinical Trials Research
    Sacramento, California 95821, United States
  • Orange County Research Center
    Tustin, California 92780, United States
  • Lynn Institute of Denver
    Denver, Colorado 80246, United States
  • Pines Clinical Research Inc.
    Hollywood, Florida 33024, United States
  • UF Health Jacksonville
    Jacksonville, Florida 32207, United States
  • Care Partners Clinical Research LLC
    Jacksonville, Florida 32277, United States
  • Sunshine Research Center
    Opa-locka, Florida 33054, United States
  • Central Florida Internist
    Orlando, Florida 32811, United States
  • Accord Clinical Research, LLC
    Port Orange, Florida 32129, United States
  • Meridien Research
    Saint Petersburg, Florida 33709, United States
  • Alternative Solutions Medical Research and Prevention Center
    Saint Petersburg, Florida 33711, United States
  • International Clinical Research - US, LLC
    Sanford, Florida 32771, United States
  • Meridien Research
    Tampa, Florida 33634, United States
  • Grady Memorial Hospital
    Atlanta, Georgia 30303, United States
  • Morehouse School of Medicine
    Atlanta, Georgia 30310, United States
  • Atlanta Center
    Atlanta, Georgia 30331, United States
  • Atlanta Clinical Research Centers
    Atlanta, Georgia 30342, United States
  • Albert F. Johary MD, PC
    Dunwoody, Georgia 30338, United States
  • Sestron Clinical Research
    Marietta, Georgia 30060, United States
  • Clinical Research Advantage, Inc./Rita B. Chuang, MD, LLC
    Marietta, Georgia 30067, United States
  • WR-Mount Vernon Clinical Research, LLC
    Sandy Springs, Georgia 30328, United States
  • Eagle's Landing Diabetes and Endocrinology
    Stockbridge, Georgia 30281, United States
  • Cedar Crosse Research Center
    Chicago, Illinois 60607, United States
  • John H. Stroger Jr. Hospital of Cook Country
    Chicago, Illinois 60612, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Investigators Research Group, LLC
    Brownsburg, Indiana 46112, United States
  • Centex Studies, Inc.
    Lake Charles, Louisiana 70601, United States
  • Gulf Regional Research and Education Services, LLC
    Metairie, Louisiana 70002, United States
  • New Orleans Center for Clinical Research
    New Orleans, Louisiana 70119, United States
  • University of Maryland School of Medicine
    Baltimore, Maryland 21201, United States
  • American Institute of Research Studies
    Baltimore, Maryland 21218, United States
  • Phillips Medical Services, PLLC
    Jackson, Mississippi 39209, United States
  • Mercy Research
    Washington, Missouri 63090-4700, United States
  • Quality Clinical Research Inc
    Omaha, Nebraska 68114, United States
  • Accent Clinical Trials
    Las Vegas, Nevada 89106, United States
  • Lovelace Scientific Resources, Inc.
    Albuquerque, New Mexico 87108, United States
  • Offic of Dr. Eric Cheng
    Brooklyn, New York 11203-1203, United States
  • Healthwise Medical Associates
    Brooklyn, New York 11206, United States
  • Modern Medical
    Brooklyn, New York 11207, United States
  • Erie County Medical Center
    Buffalo, New York 14215, United States
  • Scott Research, Inc.
    Laurelton, New York 11413, United States
  • Medex Healthcare Research, Inc.
    New York, New York 10036, United States
  • Laurelton Heart Specialist, PC
    Rosedale, New York 11422, United States
  • Metrolina Internal Medicine, PA
    Charlotte, North Carolina 28204, United States
  • PhysiqueMed Clinical Trials
    Greensboro, North Carolina 27405, United States
  • Triad Clinical Trials
    Greensboro, North Carolina 27410, United States
  • Peters Medical Research
    High Point, North Carolina 27262, United States
  • High Point Clinical Trials Center
    High Point, North Carolina 27265, United States
  • Coastal Carolina Health Care, P.A.
    New Bern, North Carolina 28562, United States
  • Hometown Urgent Care
    Columbus, Ohio 43214, United States
  • Dayton Clinical Research
    Dayton, Ohio 45406, United States
  • Today Clinical Research, Oklahoma City
    Oklahoma City, Oklahoma 73129, United States
  • Suburban Research Associates
    Media, Pennsylvania 19063, United States
  • Temple University School of Medicine
    Philadelphia, Pennsylvania 19140, United States
  • Medical Research South
    Charleston, South Carolina 29407, United States
  • TLM Medical Services, LLC
    Columbia, South Carolina 29204, United States
  • Amistad Clinical Research Center
    Columbia, South Carolina 29223, United States
  • Greenville Pharmaceutical Rsch
    Greenville, South Carolina 29615, United States
  • Mountain View Clinical Research
    Greer, South Carolina 29651, United States
  • Berkley Family Practice
    Moncks Corner, South Carolina 29461, United States
  • Carolina Cardiology Clinical Research Institute, LLC
    Rock Hill, South Carolina 29732, United States
  • Community Research Partners, Inc
    Varnville, South Carolina 29944, United States
  • Memphis Veterans Affairs Medical Center
    Memphis, Tennessee 38104, United States
  • The Green Clinic PC
    Memphis, Tennessee 38119, United States
  • Southwind Medical Specialists
    Memphis, Tennessee 38125, United States
  • University of Tennessee
    Memphis, Tennessee 38163, United States
  • Diagnostic Clinic of Houston
    Houston, Texas 77004, United States
  • Cullen Family Practice, PLLC
    Houston, Texas 77051, United States
  • Centex Studies, Inc.
    Houston, Texas 77058, United States
  • Texas Center for Drug Development, Inc.
    Houston, Texas 77081, United States
  • Kelsey-Seybold Clinic
    Houston, Texas 77096, United States
  • Hillcrest Family Health Center
    Waco, Texas 76710, United States
  • Millennium Clinical Trials LLC
    Arlington, Virginia 22203, United States
  • York Clinical Research, LLC
    Norfolk, Virginia 23510, United States
  • Dominion Medical Associates, Inc.
    Richmond, Virginia 23219, United States
  • Clinical Research Partners, LLC
    Richmond, Virginia 23235, United States
  • Family Medical Clinic
    Milwaukee, Wisconsin 53216, United States
09

References and documents

Publications

  • Ferdinand KC, Harrison D, Johnson A. The NEW-HOPE study and emerging therapies for difficult-to-control and resistant hypertension. Prog Cardiovasc Dis. 2020 Jan-Feb;63(1):64-73. doi: 10.1016/j.pcad.2019.12.008. Epub 2020 Jan 8. PubMed 31923435 ↗
  • Ferdinand KC, Izzo JL, Lee J, Meng L, George J, Salsali A, Seman L. Antihyperglycemic and Blood Pressure Effects of Empagliflozin in Black Patients With Type 2 Diabetes Mellitus and Hypertension. Circulation. 2019 Apr 30;139(18):2098-2109. doi: 10.1161/CIRCULATIONAHA.118.036568. PubMed 30786754 ↗
  • Ferdinand KC, Seman L, Salsali A. Design of a 24-week trial of empagliflozin once daily in hypertensive black/African American patients with type 2 diabetes mellitus. Curr Med Res Opin. 2018 Feb;34(2):361-367. doi: 10.1080/03007995.2017.1405800. Epub 2017 Nov 29. PubMed 29139301 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2014 to primary completion in May 2017, 33 months.

Results were first posted in Jul 2018, 1 year 2 months after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 33 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2014
First posted
Jul 8, 2014
StartActual
Jul 25, 2014
Primary completionActual
May 18, 2017
CompletionActual
May 18, 2017
Results first posted
Jul 31, 2018
Last update
Jul 31, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02182830
Responsible party
Sponsor
First posted
Jul 8, 2014
Start date
Jul 25, 2014
Primary completion
May 18, 2017
Completion
May 18, 2017
Results posted
Jul 31, 2018
Last update
Jul 31, 2018

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion